Regeneron Expands Dupixent Indications and Partners with Telix Pharmaceuticals

Regeneron Pharmaceuticals, in collaboration with Sanofi, has received approval from the European Commission for the use of Dupixent in treating moderate to severe chronic spontaneous urticaria in children aged 2 to 11. This new indication broadens Dupixent's existing label in Europe and is backed by clinical data highlighting the significant unmet medical needs in this pediatric population.

In addition to the Dupixent approval, Regeneron has announced a partnership with Telix Pharmaceuticals. The two companies will work together to develop and commercialize next-generation radiopharmaceutical therapies aimed at treating solid tumors. This collaboration marks Regeneron's entry into the radiopharmaceuticals sector, expanding its portfolio in innovative treatment options.

© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

Source: KLEA News